Evidence map›Paper›PMID 42703497›Full record

ArticleJTO clinical and research reports2026

Lung Cancer Screening-Eligible Population From 2000 to 2050 in Argentina: A Simulation Study Brief Report.

M Victoria Salgado, Jihyoun Jeon, Pianpian Cao, Iris Boyeras, Raul Mejia, Rafael Meza

Abstract read
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

M Victoria SalgadoCentro de Estudios de Estado y Sociedad, Ciudad de Buenos Aires, Argentina.
Jihyoun JeonDepartment of Epidemiology, University of Michigan, Ann Arbor, Michigan.
Pianpian CaoDepartment of Public Health, Purdue University, West Lafayette, Indiana.
Iris BoyerasSanatorio Sagrado Corazón, Ciudad de Buenos Aires, Argentina.
Raul MejiaCentro de Estudios de Estado y Sociedad, Ciudad de Buenos Aires, Argentina.
Rafael MezaDepartment of Population Health Sciences, BC Cancer Research Institute, Vancouver, British Columbia, Canada.

Funding

Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment InterventionsU01CA253858 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DE KONING, HARRY J, HOLFORD, THEODORE R · 2020 to 2025
$8.4M
NCI NIH HHS U01 CA253858
6 · The paper itself

Abstract

Introduction: In Argentina, lung cancer remains the leading cause of cancer death. However, the National Cancer Institute lacks formal lung cancer screening (LCS) recommendations. We projected LCS-eligible populations from 2000 to 2050 under varying screening criteria. Methods: We used Argentina's version of the Cancer Intervention and Surveillance Modeling Network Smoking History Generator. This microsimulation model generates cohort-specific smoking histories by age and sex. We projected the number of LCS-eligible individuals in Argentina from 2000 to 2050 under (1) the U.S. Preventive Services Task Force 2021 criteria (ages 50-80 y, ≥20 pack-years, currently smoke or have quit within the past 15 y) and (2) the U.S. National Lung Screening Trial criteria (ages 55-74, ≥30 pack-years, currently smoke or have quit within the past 15 y). Results: Under the U.S. Preventive Services Task Force 2021 criteria, LCS-eligible individuals are projected to plateau at 1.6 million between 2018 and 2036, declining to 1.3 million by 2050; the proportion of eligible individuals aged 50 to 80 years is expected to fall from 15.1% in 2018 to 7.8% in 2050 amid population growth and declining smoking rates. Under the National Lung Screening Trial criteria, eligibility peaks at 0.8 million in 2016 and declines to 0.6 million by 2050; the proportion of eligible individuals aged 55 to 74 years decreases from 11.2% to 5.3% over this period. Conclusions: Demand for LCS will gradually decrease as fewer individuals meet the eligibility criteria. Despite projected declines, between 0.5 million and more than 1 million Argentinians will remain LCS eligible by mid-century, supporting consideration of a national screening program to reduce lung cancer mortality.

Indexed as

ArgentinaEligibilityLow- and middle-income countriesLung cancer screening

Identifiers

PMID42703497
PMCPMC13546832

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.